FindTrial
Sign In

Effects of Plasmapheresis on Mycophenolic Acid Concentrations in Kidney Transplant Patient

Effects of Plasmapheresis on Mycophenolic Acid Concentrations in Kidney Transplant Patient

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20190211001
Enrollment
9
Registered
2019-02-11
Start date
2018-01-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney transplant recipient mycophenolic acid plasmapheresis

Interventions

kidney transplant recipient
Treatment

Sponsors

Ratchadapiseksompotch fund
Lead Sponsor
Ratchadapiseksompotch fund
Collaborator

Eligibility

Sex/Gender
Male
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Kidney transplant recipientA ged over 18 years Taking mycophenolate mofetil 2 gm per day Undergoing plasmapheresis

Exclusion criteria

Exclusion criteria: Patients with serum albumin < 2 g/dL

Design outcomes

Primary

MeasureTime frame
MPA AUC reduction 1 year MPA AUC0&#45;12hr—

Secondary

MeasureTime frame
Duration of last dose of MPA before undergoing plasmapheresis 1 years MPA AUC—

Countries

Thailand

Contacts

Public ContactSudarat piyasiridej

KIng Chulalongkorn Memorial Hospital

yam_med16@hotmail.com66849426453

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026